Suppression of Drug Resistance in Dengue Virus
ABSTRACT Dengue virus is a major human pathogen responsible for 400 million infections yearly. As with other RNA viruses, daunting challenges to antiviral design exist due to the high error rates of RNA-dependent RNA synthesis. Indeed, treatment of dengue virus infection with a nucleoside analog res...
Guardado en:
Autores principales: | Roberto Mateo, Claude M. Nagamine, Karla Kirkegaard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fca0a1a02dcf4272b992bde8f4d1ca32 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity
por: Jasmine Moshiri, et al.
Publicado: (2020) -
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
por: J. A. Swanstrom, et al.
Publicado: (2016) -
Dengue Virus Genome Uncoating Requires Ubiquitination
por: Laura A. Byk, et al.
Publicado: (2016) -
Role of Complement in Dengue Virus Infection: Protection or Pathogenesis?
por: Sujan Shresta
Publicado: (2012) -
Complement-Mediated Neutralization of Dengue Virus Requires Mannose-Binding Lectin
por: Panisadee Avirutnan, et al.
Publicado: (2011)